In-house R&D projects open for out-licensing and/or co-development partnerships:

Pharmahungary Group runs in-house R&D projects for the development of therapies in cardiovascular and metabolic diseases up to phase II clinical stage. Investors and co-development partners are welcome:

The following in-house diagnostic R&D projects of Pharmahungary Group are in the early clinical phase of development:

  • Infarnosys: (www.infarnosys.com): novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment. SME Instrument Phase I winner project.
  • Vezics: (www.vezics.com): modular and scalable chromatography platform for high-quality exosome isolation for biomarker and therapy. SME Instrument Phase I winner project.
  • miRNAtarget: (www.mirnatarget.com): bioinformatics project for target prediction: miRNA targets. Online version is available!